Cambrex Stock Price, News & Analysis (NYSE:CBM)

Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."

Cambrex Co. (NYSE:CBM) posted its quarterly earnings data on Thursday, August, 2nd. The biotechnology company reported $0.74 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.05. The biotechnology company had revenue of $152.05 million for the quarter, compared to analyst estimates of $132.78 million. Cambrex had a net margin of 9.41% and a return on equity of 8.20%. Cambrex's quarterly revenue was up 13.0% on a year-over-year basis. During the same period last year, the firm posted $0.76 EPS. View Cambrex's Earnings History.

Cambrex is scheduled to release their next quarterly earnings announcement on Thursday, November 14th 2019. View Earnings Estimates for Cambrex.

5 brokerages have issued 12 month target prices for Cambrex's stock. Their predictions range from $43.00 to $60.00. On average, they expect Cambrex's stock price to reach $52.40 in the next year. This suggests that the stock has a possible downside of 12.1%. View Analyst Price Targets for Cambrex.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cambrex.

Press coverage about CBM stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cambrex earned a media sentiment score of -3.9 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for Cambrex.

Cambrex saw a decrease in short interest in September. As of September 30th, there was short interest totalling 1,110,000 shares, a decrease of 9.0% from the August 30th total of 1,220,000 shares. Based on an average daily volume of 694,300 shares, the days-to-cover ratio is presently 1.6 days. Approximately 3.3% of the shares of the company are short sold. View Cambrex's Current Options Chain.

Some companies that are related to Cambrex include Thermo Fisher Scientific (TMO), Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), PerkinElmer (PKI), BIO-TECHNE (TECH), Bruker (BRKR), Charles River Laboratories Intl. (CRL), Luminex (LMNX), Pacific Biosciences of California (PACB), Fluidigm (FLDM), Harvard Bioscience (HBIO) and aTyr Pharma (LIFE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cambrex investors own include Celgene (CELG), Illumina (ILMN), AbbVie (ABBV), Gilead Sciences (GILD), NVIDIA (NVDA), CVS Health (CVS), Juno Therapeutics (JUNO), Intel (INTC), Western Digital (WDC) and Under Armour (UAA).

Cambrex's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Summit Creek Advisors LLC (0.26%), Confluence Investment Management LLC (0.21%), State of Alaska Department of Revenue (0.08%), Strs Ohio (0.05%), Assenagon Asset Management S.A. (0.04%) and Nisa Investment Advisors LLC (0.02%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.

CBM stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Confluence Investment Management LLC, Envestnet Asset Management Inc. and Nisa Investment Advisors LLC. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Shawn Cavanagh and Steven M Klosk. View Insider Buying and Selling for Cambrex.

CBM stock was bought by a variety of institutional investors in the last quarter, including Strs Ohio, State of Alaska Department of Revenue and Assenagon Asset Management S.A.. View Insider Buying and Selling for Cambrex.

Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CBM stock can currently be purchased for approximately $59.58.

Cambrex has a market capitalization of $2.01 billion and generates $532.09 million in revenue each year. The biotechnology company earns $92.41 million in net income (profit) each year or $2.77 on an earnings per share basis. Cambrex employs 1,732 workers across the globe.View Additional Information About Cambrex.

The official website for Cambrex is http://www.cambrex.com/.

Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]